Scientists Test the Effects of Inhaling Synthetic 5-MeO-DMT
Some changes occured to biomarkers for stress and inflammation. The subjective effects reveal more evidence of the entourage effect.
Depression - Page 5
Usona Follows COMPASS in Receiving Breakthrough Therapy Designation for Psilocybin to Treat Depression
This means the FDA will work to expedite the development and review of psilocybin so it can get to patients with major depressive disorder as soon as possible.
Usona Institute Beginning Phase 2 Clinical Trials Using Psilocybin to Treat Major Depressive Disorder
Enrollment of study volunteers is expected to start within the next two months.
Single Inhalation of Dried Toad Secretions Provides Sub-Acute and Sustained Benefits
Increased mindfulness and decreased anxiety, depression, and stress were seen right away, becoming more significant four weeks after dosing.
Is Esketamine the First FDA-Approved Psychedelic Drug?
The answer is yes and no. It's a matter of perspective.
Studies Find 5-MeO-DMT Improves Symptoms of Anxiety and Depression
Improvements in depression and anxiety are associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning.
TheraPsil Seeks Permission From Health Canada to Use Psilocybin Treatments for Dying Patients
Bruce Tobin is asking Health Canada to approve psilocybin to treat anxiety and depression in end-of-life patients.
Analysis of the Future Psilocybin Pharmaceutical Market
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.
Johns Hopkins Researchers Call for Rescheduling Psilocybin
Researchers push to move psilocybin from Schedule I to Schedule IV if Phase III clinical trials are successful.
Psilocybin Receives FDA Breakthrough Treatment Designation
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.